Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening
Wednesday, January 08, 2025QUANTRO Therapeutics a pioneer in the discovery of firstinclass transcription factor targeting cancer treatments announced today that the company has successfully completed its first tentarget multiplexscreening campaign which yielded validated hits...
Repligen Launches the CTech™ SoloVPE® PLUS System
Tuesday, January 07, 2025Repligen Corporation a life sciences company focused on bioprocessing technology leadership today announced the commercial launch of its CTech SoloVPE PLUS System the most advanced UVbased Variable Pathlength Technology system now available to biopha...
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
Tuesday, January 07, 2025Zealand Pharma AS CVRno a biotechnology company focused on the discovery and development of innovative peptidebased medicines announced that Chief Executive Officer Adam Steensberg will present an overview of the company at the rd Annual JP Morgan H...
LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy
Monday, January 06, 2025LPOXY Therapeutics Inc a clinicalstage biopharmaceutical company focused on innovative therapies for infectious disease prevention announced today that it has signed a term sheet to acquire selected assets from Xeno Biosciences Inc Xeno The assets in...
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
Saturday, January 04, 2025Rakovina Therapeutics Inc a biopharmaceutical company focused on the development of new cancer therapies based on novel DNAdamage response technologies is pleased to announce its participation in events and meetings being held alongside the rd Annual...
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics
Friday, January 03, 2025Atavistik Bio a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the bodys natural regulators today announced that it has entered into a research collaboration with Pfizer to accelera...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Friday, January 03, 2025Altamira Therapeutics Ltd a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver today announced that its nanoparticlebased delivery platform was successfully tested also for circular mRNA In vitro...
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
Tuesday, December 31, 2024RenovoRx Inc a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath a novel FDAcleared delivery system today highlighted its strong intellectual property IP position as it moves forward with commercial pla...
European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
Monday, December 30, 2024JanssenCilag International NV a Johnson Johnson company today announced that the European Commission EC has approved a Type II variation extension of indication for RYBREVANT amivantamab in combination with LAZCLUZE lazertinib for the firstline trea...
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
Friday, December 27, 2024Axcelead Drug Discovery Partners Inc announced that it has entered into a drug discovery service agreement with Astellas Pharma Inc to explore new candidate compounds for targeted protein degraders
